Single-cell transcriptomics has revolutionized the study of cellular diversity and function by enabling gene expression ...

AWS’s framework will speed up the analysis of ElevateBio’s large protein datasets, hinting at promising drug candidates.

Johns Hopkins Medicine laboratory scientists say they have developed a potential new way to treat a variety of rare genetic ...

Initiated Phase 1 Single Ascending Dose Trial of DT-216P2 in Healthy Volunteers; Friedreich Ataxia (FA) Patient Dosing to Begin in mid-2025Dosing ...

Development strategies designed to reduce the unknowns so that cell and gene therapy innovators can develop robust processes ...

Offering free solutions can generate goodwill and strengthen relationships with both existing and potential customers. When a ...

Generative AI combined with ElevateBio Life Edit's immense library of CRISPR systems and proprietary data from experiments will drive the synthesis and optimization of novel CRISPR drugs for genetic ...

In 2025, Cellectis will continue to focus its efforts and expenses on advancing its core clinical trials BALLI-01 and NATHALI ...

PEMBROKE — The Museum of the Southeast American Indian is establishing the Lloyd Oxendine Artist-in-Residence program beginning March 17.

Gene regulatory networks are important in development ... activity and function as biological ‘oracles’ aiding the design of synthetic enhancers with tailored cell-type-specific or cell ...

March 10, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics ...

Prof Mark Smales, a principal investigator at NIBRT, has received more than €3.5m from Research Ireland to advance biotheraupeutics.